Heart:冠脉造影与心衰的预后有关?

2017-08-14 nanchao.H MedSci原创

对于较严重的心衰患者,往往会行冠脉造影术,然而,心衰患者冠状动脉造影术的决定因素和相关临床结果知之甚少。 本研究(BIOSTAT-CHF)纳入了2516名有明显临床症状的心衰患者,包括住院治疗的病人和院外治疗的患者。研究结果显示,有315名(12.5%)心衰患者在出现了明显临床症状后30天内接受了冠脉造影术。在接受了冠脉造影的患者中,大多数是住院病人,伴有较明显的急性冠脉综合征,肌钙蛋白I的

对于较严重的心衰患者,往往会行冠脉造影术,然而,心衰患者冠状动脉造影术的决定因素和相关临床结果知之甚少。

本研究(BIOSTAT-CHF)纳入了2516名有明显临床症状的心衰患者,包括住院治疗的病人和院外治疗的患者。研究结果显示,有315名(12.5%)心衰患者在出现了明显临床症状后30天内接受了冠脉造影术。在接受了冠脉造影的患者中,大多数是住院病人,伴有较明显的急性冠脉综合征,肌钙蛋白I的水平也较高,更年轻,并且肾功能相对更好(所有的p0.01)。另外,接受了冠脉造影的患者的心衰住院风险更低(HR=0.71, 95% CI 0.57-0.89, p=0.003),死亡率也更低(HR=0.59, 95% CI 0.43-0.80, p=0.001)。在行冠脉造影术的患者中,伴有冠脉狭窄的患者(39%)的临床预后要更差(HR =1.71, 95% CI 1.10-2.64, p=0.016)。

研究结果表明,在有明显症状的心衰患者中,仅有<13%的患者接受了冠脉造影术。相比于没有接受冠脉造影的患者,接受了冠脉造影术患者的不良预后结局发生风险要明显降低。

原始出处:

Joao P et al.Coronary angiography in worsening heart failure: determinants, findings and prognostic implications.Heart.2017 Aug.

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1356466, encodeId=b07c135646632, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447188, encodeId=6df7144e1886e, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494039, encodeId=04d6149403999, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562661, encodeId=7df71562661a9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233454, encodeId=8bf3233454e7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Aug 14 11:04:15 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-08-16 zhaojie88
  2. [GetPortalCommentsPageByObjectIdResponse(id=1356466, encodeId=b07c135646632, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447188, encodeId=6df7144e1886e, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494039, encodeId=04d6149403999, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562661, encodeId=7df71562661a9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233454, encodeId=8bf3233454e7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Aug 14 11:04:15 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1356466, encodeId=b07c135646632, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447188, encodeId=6df7144e1886e, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494039, encodeId=04d6149403999, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562661, encodeId=7df71562661a9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233454, encodeId=8bf3233454e7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Aug 14 11:04:15 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-08-16 sodoo
  4. [GetPortalCommentsPageByObjectIdResponse(id=1356466, encodeId=b07c135646632, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447188, encodeId=6df7144e1886e, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494039, encodeId=04d6149403999, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562661, encodeId=7df71562661a9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233454, encodeId=8bf3233454e7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Aug 14 11:04:15 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-08-16 slcumt
  5. [GetPortalCommentsPageByObjectIdResponse(id=1356466, encodeId=b07c135646632, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447188, encodeId=6df7144e1886e, content=<a href='/topic/show?id=dd2f31009da' target=_blank style='color:#2F92EE;'>#冠脉造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31009, encryptionId=dd2f31009da, topicName=冠脉造影)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/g?b=oidb&k=l9h0OhA0BicNC4kpEUl4AeA&s=100&t=1587635346, createdBy=61865326685, createdName=李研东, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1494039, encodeId=04d6149403999, content=<a href='/topic/show?id=3e34949e333' target=_blank style='color:#2F92EE;'>#造影#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94973, encryptionId=3e34949e333, topicName=造影)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=908d9134595, createdName=sodoo, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562661, encodeId=7df71562661a9, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Wed Aug 16 01:55:00 CST 2017, time=2017-08-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=233454, encodeId=8bf3233454e7, content=学习一下, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo6KcicAVC1MwuOgo3iaicb1Imgk1yIfnvr6oXzibcAFB6puAyNJXbzWhNuLqaFYBVRWjh7rghkvFLPxMAfD5ib3nXwVD/0, createdBy=bed21972958, createdName=wxl882001, createdTime=Mon Aug 14 11:04:15 CST 2017, time=2017-08-14, status=1, ipAttribution=)]
    2017-08-14 wxl882001

    学习一下

    0

相关资讯

Circulation:腹部动脉瘤治疗效果的大样本临床研究

腹部动脉瘤(AAA)一旦破裂,死亡率极高。目前, AAA的发病率呈下降趋势,治疗手段也发生了改变,逐渐转向血管内动脉瘤修复(EVAR)。近日,在国际心血管权威杂志《Circulation》上发表了一篇旨在评估腹部动脉瘤治疗手段的改变对AAA预后影响的临床研究。本研究纳入了2000年至2014年芬兰所有接受AAA治疗的患者,在此期间由于接受AAA治疗而死亡的患者数据也纳入分析。在过去的50年里,AA

JACC:经皮除颤器植入的安全性和疗效性研究

经皮电复律除颤器的植入(S-ICD)是用来治疗室性心律失常的技术,S-ICD临床结果和成本效益因素评价(EFFORTLESS S-ICD)的数据库记录了985名患者5年的随访预后情况。近日,在国际心血管权威杂志JACC上发表了一篇旨在通过EFFORTLESS S-ICD数据库评估分析S-ICD的安全性和不良休克发生率的临床研究。本研究的主要终点事件是术后30天和360天的并发症,心房颤动或室上性心

Heart:肺血管扩张治疗不能改善艾森曼格综合征患者的临床预后

艾森曼格综合征(ES)是一种严重的由先天性心脏病导致的肺动脉高压症,预后差。近日,在国际心血管权威杂志《Heart》上发表了一篇旨在研究影响艾森曼格综合征预后的临床因素以评估肺血管扩张治疗(AT)对其影响的临床研究。本研究纳入了自2004年1月起来自12个成人先心病诊治中心的253名ES患者,并对其临床数据进行了全面的分析和评估。研究结果显示,ES患者大多数为女性(60%),平均年龄31岁(SD1

JAHA:肿瘤治疗药物贝伐单抗会增加心血管不良事件风险!

免疫调节药贝伐单抗(bevacizumab)被用于治疗多种类型的癌症,其原理是通过抑制血管内皮生长因子(VEGF)从而抑制肿瘤的血管再生。然而,不良的心血管事件会限制该药的使用,需要进一步的随访,调整治疗策略。本荟萃分析研究搜索了截至2016年11月MEDLINE、 Cochrane、 EMBASE和Web of Science数据库的相关随机对照临床研究,共纳入了来自22个研究中的20050例癌

CHC2017:美国NIH科学中心主任:直面真相!心血管病已成为中国不可承受之重

美国NIH心肺血液研究所转化研究与应用科学中心主任George A. Mensah 认为,现阶段全球心血管疾病负担的真相是,相比全球心血管死亡率的下降,中国心血管疾病死亡率仍在逐年上升。

JACC:经皮自膨式主动脉瓣置换术的疗效和安全性研究

目前,经皮二代自膨式主动脉瓣置换术的临床预后尚缺乏大型临床研究的数据。近日,在国际心血管权威杂志JACC上发表了一篇旨在记录和评估在严重的主动脉瓣狭窄患者中应用二代自膨式心脏瓣膜(THV)行经皮主动脉瓣置换术(TAVR)的预后疗效的临床研究。本研究是多中心回顾性研究,自2016年1月至2016年12月共纳入1038例应用THV行TAVR的主动脉瓣狭窄患者,平均年龄是81.8 ± 6.2岁,女性占6